News & Updates

According to a retrospective, territory-wide, case-based study, the mRNA-based BNT162b2 vaccine and inactivated CZ02 vaccine were partially effective against SARS-CoV-2 infection in children and adolescents during the Omicron BA.2 wave in Hong Kong. 

A study from Israel validated the safety of the fourth BNT162b2 mRNA COVID-19 vaccine (ie, second booster) using data from a retrospective and a prospective cohort.

Full vaccination with the SARS-CoV-2 BNT162b2 vaccine reduced infection and hospitalization due to the delta and omicron variants of the SARS-CoV-2 infection, with an added benefit against the omicron variant in individuals who received a booster dose, according to a national study of Singaporean adolescents.

Patients with mild COVID-19 may encounter a few health concerns for several months following SARS-CoV-2 infection, but these outcomes tend to resolve within a year from diagnosis, reveals a study.

The benefit of anakinra treatment in patients hospitalized with COVID-19 is consistent regardless of age, sex, comorbidities, and suPAR* levels, according to subgroup analysis of the SAVE-MORE trial.

A low-calorie total diet replacement program (Counterweight-Plus) is safe and improves asthma control and quality of life in patients with difficult-to-treat asthma and obesity, according to 16-week data from a recent study.